After a reverse merger in December, the blood glucose monitor implant company Senseonics is already publicly traded, albeit on the OTC markets. Now, it's filed to raise up to $51.8 million in an IPO-like offering, after which it proposes to bump up to the NYSE market and trade under the ticker symbol "SENS."
Risk-sharing researcher Evotec said it's advancing an early-stage Alzheimer's disease project alongside partner Johnson & Johnson, working to find new approaches to treating the neurodegenerative disorder.
Contract drug developer AMRI bolstered its client roster with three new agreements making use of its R&D, manufacturing and marketing divisions.
Catalent Pharma Solutions is loaning out one of its drug development platforms to Roche in a heavily back-loaded deal, signing on to reap as much as $619 million.
Spark Therapeutics, at work on gene therapies for rare diseases, laid out an ambitious three-year plan that would see its top candidate win FDA approval and 9 others enter clinical trials.
Medtronic stealthily acquired the OsteoCool RF Ablation System from Baylis Medical last month. Now, the medical device giant has launched the cooled radiofrequency (RF) ablation tech in the U.S. after it received 510(k) clearance from the FDA in November. Baylis and Medtronic have also partnered for further innovations to the system.
Vice President Joe Biden fleshed out his plans to take the lead on a global effort to bolster cancer research, hoping to unite industry and academia to push new therapies forward.
Royal Philips and EDBI, the corporate investment arm of the Singapore Economic Development Board, have agreed to jointly invest in digital health companies that are working on population health management tools for the Asian market. The idea is to use Singapore as a launch point from which to reach further into Asia.
Dexcom offered investors a glimpse of its high-profile partnership with Google Life Sciences to develop a next-generation continuous glucose monitor that would be tiny, disposable and affordable for the world's masses of Type 2 diabetics. A product isn't expected to result for another 5 years or so--but Dexcom has committed $40 million to the project, making this its largest R&D expense, the company said at this year's J.P. Morgan Healthcare Conference in San Francisco.
South San Francisco's Iconic Therapeutics raised $40 million in Series C cash to support its work on treatments for eye cancer, moving toward clinical trials with its ocular melanoma program.